Supernus Pharmaceuticals Payment date

Payment date of Supernus Pharmaceuticals, Inc.

N/A
Dividend date is the payment date scheduled for paying out declared dividends.

The dividend date or payment date is the date on which dividends will be paid to shareholders. Only shareholders who owned the stock before an ex-dividend date are entitled to dividends.


About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy. The company's product candidates comprise SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder (ADHD); and SPN-812, a viloxazine hydrochloride, which has completed Phase IIb trial that is used for the treatment of ADHD. It also develops SPN-809, a viloxazine hydrochloride, which is in Phase II ready clinical trial for the treatment of depression. The company markets its products through wholesalers and pharmaceutical distributors. Supernus Pharmaceuticals, Inc. was founded in 2005 and is based in Rockville, Maryland.

Companies with SMA 200 similar to Supernus Pharmaceuticals